Immunoprecise Antibodies Ltd Revenue Growth Rates (IPA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Immunoprecise Antibodies Ltd   (NASDAQ: IPA)
 

IPA's Revenue Growth by Quarter and Year

Immunoprecise Antibodies Ltd 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IPA Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter April -
3rd Quarter January 3.00
2nd Quarter October 2.97
1st Quarter July 2.30
FY 8.27

IPAs Annual Revenue
Immunoprecise Antibodies Ltd 's Revenue in the fiscal year 2025 $ 17.60 millions
Immunoprecise Antibodies Ltd 's Revenue in the fiscal year 2024 $ 18.78 millions
Immunoprecise Antibodies Ltd 's Revenue in the fiscal year 2023 $ 15.83 millions
Immunoprecise Antibodies Ltd 's Revenue in the fiscal year 2022 $ 15.44 millions
Immunoprecise Antibodies Ltd 's Revenue in the fiscal year 2021 $ 10.52 millions




IPA Revenue third quarter 2025 Y/Y Growth Comment
Immunoprecise Antibodies Ltd achieved in the third quarter 2025, above Company average Revenue rise of 56.21% year on year, to $ 3.00 millions.

Looking into third quarter 2025 results within Major Pharmaceutical Preparations industry 67 other companies have achieved higher Revenue growth. While Immunoprecise Antibodies Ltd ' s Revenue jump of 56.21% ranks overall at the positon no. 384 in the third quarter 2025.


IPA Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter April - - - -
3rd Quarter January 56.21 % 6.08 % - -
2nd Quarter October -84.19 % - - -
1st Quarter July 17.35 % - - -
FY   - 1798.9 % -88.57 % -

Financial Statements
Immunoprecise Antibodies Ltd 's third quarter 2025 Revenue $ 3.00 millions IPA's Income Statement
Immunoprecise Antibodies Ltd 's third quarter 2024 Revenue $ 1.92 millions Quarterly IPA's Income Statement


IPA Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter April - 509.9 % - -
3rd Quarter January 0.98 % -89.78 % - -
2nd Quarter October 29.13 % 858.16 % - -
1st Quarter July -80.36 % - - -
FY (Year on Year)   - 1798.9 % -88.57 % -


Back to IPA Growth rate Comparisons >> Back to IPA Growth rate Comparisons >>


Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #68
Healthcare Sector #121
Overall #384

Revenue Y/Y Growth Statistics
High Average Low
56.2 % 23.21 % -37.66 %
 
Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #68
Healthcare Sector #121
Overall #384
Revenue Y/Y Growth Statistics
High Average Low
56.2 % 23.21 % -37.66 %
 

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Immunoprecise Antibodies Ltd 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
509.75 % 34.46 % -100 %
(Apr 30 2025)  


IPA's III. Quarter Q/Q Revenue Comment
Immunoprecise Antibodies Ltd achieved in the III. Quarter 2025 below company average Revenue growth of 0.98% quarter on quarter, to $ 3.00 millions.

Although the III. Quarter 2025 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -89.78% growth in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Revenue quarter on quarter growth. While Immunoprecise Antibodies Ltd 's Revenue growth quarter on quarter, overall rank is 1797.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #267
Overall #1797
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #267
Overall #1797
Revenue Q/Q Growth Statistics
High Average Low
509.75 % 34.46 % -100 %
(Apr 30 2025)  


IPA's III. Quarter Q/Q Revenue Comment
Immunoprecise Antibodies Ltd achieved in the III. Quarter 2025 below company average Revenue growth of 0.98% quarter on quarter, to $ 3.00 millions.

III. Quarter 2025 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -89.78% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Revenue quarter on quarter growth. While Immunoprecise Antibodies Ltd 's Revenue growth quarter on quarter, overall rank is 1797.


Immunoprecise Antibodies Ltd 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Apr 30 2025)		 12 Months Ending
(Apr 30 2024)		 12 Months Ending
(Apr 30 2023)		 12 Months Ending
(Apr 30 2022)		 12 Months Ending
Cumulative Revenue 12 Months Ending $ 17.60 $ 18.78 $ 15.83 $ 15.44 $ 0.00
Y / Y Revenue Growth (TTM) -6.28 % 18.65 % 2.54 % 46.7 % -
Year on Year Revenue Growth Overall Ranking # 830 # # # #
Seqeuential Revenue Change (TTM) -6.28 % 18.65 % 2.54 % 46.7 % -
Seq. Revenue Growth (TTM) Overall Ranking # 830 # # # # 2800


Cumulative Revenue growth Comment
For the 12 months ended Apr 30 2025 Immunoprecise Antibodies Ltd reported a decrease in Revenue by -6.28% year on year, to $18 millions, compare to the 18.65% growth at Apr 30 2024.

In the Healthcare sector 110 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from to 830.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 61
Healthcare Sector # 111
Overall # 342

Revenue TTM Y/Y Growth Statistics
High Average Low
46.7 %
 15.4 %
-6.28 %
(Apr 30 2022)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 61
Sector # 111
S&P 500 # 342
Cumulative Revenue growth Comment
For the 12 months ended Apr 30 2025 Immunoprecise Antibodies Ltd reported a decrease in Revenue by -6.28% year on year, to $18 millions, compare to the 18.65% growth at Apr 30 2024.

In the Healthcare sector 110 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from to 830.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 61
Healthcare Sector # 111
Overall # 342

Revenue TTM Y/Y Growth Statistics
High Average Low
46.7 %
15.4 %
-6.28 %
(Apr 30 2022)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 61
Sector # 111
S&P 500 # 342




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IPA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Jan 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jan 31 2026
Kestra Medical Technologies Ltd 64.34%$ 64.336 millions
Immunoprecise Antibodies Ltd 56.20%$ 56.205 millions
Zeo Scientifix Inc 32.66%$ 32.661 millions


About Immunoprecise Antibodies Ltd Revenue Growth Rates (IPA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Mindwalk Holdings Corp (CIK 1715925).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-312694
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Mindwalk Holdings Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.